Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial

202516 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 406, Issue 10499, pp. 163-173

Field-Weighted Citation Impact: 19.25